Incyte | Zinsaufwendungen Für Schuld



Interest Expense On Debt Veränderung Datum
Agios Pharmaceuticals 3.01M 10.05M 2024-12
Alnylam Pharmaceuticals USD 38.97M 4.6M 2024-12
Amgen USD 747M 29M 2024-12
Biogen USD 60M 200K 2024-12
BioMarin Pharmaceutical USD 2.58M 391K 2024-12
Bristol-Myers Squibb USD 496M 9M 2024-12
Eli Lilly USD 224.7M 78.4M 2024-12
Exelixis 23.4M 3.9M 2023-09
Gilead Sciences USD 248M 10M 2024-12
Incyte USD 419K 355K 2024-12
Ionis Pharmaceuticals USD 2.59M 70K 2024-12
MacroGenics USD 0 6K 2024-09
Merck USD 328M 2M 2024-12
Moderna USD 6M 0 2024-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 275M 11M 2024-12
Novartis USD 275M 11M 2024-12
Pfizer USD 739M 45M 2024-12
PTC Therapeutics USD 42.11M 1.09M 2024-09
Regeneron Pharmaceuticals USD 10.5M 3.3M 2024-12
Sarepta Therapeutics USD 4.92M 86K 2024-09
Ultragenyx Pharmaceutical 15.52M 190K 2024-12
Vertex Pharmaceuticals USD 2.8M 4.7M 2024-12



Incyte Zinsaufwendungen Für Schuld - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2025.